[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colo-rectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colo-rectal-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,42,80,111,139,166,207,229,252,276,299,323,361,390,410,437,461,483,514,535,560,587,620,645,664],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100597401","phase-2-a-phase-ii-platform-study-to-evaluate-treatment-with-cemiplimab-monotherapy-or-cemiplimab-plus-fianlimab-or-other-novel-combinations-in-patients-with-colorectal-cancer-with-minimal-residual-disease-following-definitive-surgery-and-chemotherapy-empire-100597401",false,"NCT07058012","A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)","A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab and Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy","EMPIRE","Inclusion Criteria:\n\n* The patient must have consented to participate and, prior to beginning specific study procedures, must have signed and dated appropriate Institutional Review Board (IRB) -approved consent forms that conform to federal and institutional guidelines for study treatment.\n* Patients must be greater than or equal to18 years old.\n* The ECOG performance status must be 0-1.\n* Patients must have confirmed histologic and pathologic stage II\u002FIII colon, stage II\u002FIII rectal, or oligometastatic stage IV colorectal adenocarcinoma (per AJCC 8th edition).\n* There must be documentation by CT scan with contrast that the patient has no definitive evidence of (non-resected or non-ablated) metastatic disease including assessment of chest, abdomen, and pelvis at the time of study enrollment\n* All patients must have had a complete (R0) resection of their primary tumor and resected or ablated (radiofrequency ablation, stereotactic body radiation therapy \\[SBRT\\], microwave ablation, etc.\\]) oligometastatic disease if present AND at least 3 months of a standard systemic chemotherapy regimen (e.g., FOLFOX or CAPOX or fluoropyrimidine monotherapy). This includes either adjuvant chemotherapy for colon cancer or perioperative (adjuvant or neoadjuvant) chemotherapy for rectal cancer or oligometastatic colon or rectal cancer. Chemoradiotherapy for rectal cancer (as a component of curative treatment) is acceptable. NOTE: Patients who achieve a clinical complete response and opt for a non-operative approach to their primary tumor management are not eligible.\n\n  * Patients must be ctDNA-positive by an assay run in any CLIA-certified lab obtained within 2 weeks to 12 months following completion of definitive all curative therapy for colorectal cancer.\n  * Tumor status of microsatellite stability (MSS) or Proficient mismatch repair (pMMR) is confirmed through a standard of care assay through a CLIA-certified lab.\n* At the time of study entry, blood counts performed within 28 days prior to study entry must meet the following criteria:\n\n  * ANC must be greater than or equal to (≥) 1000\u002Fmm3,\n  * Platelet count must be ≥ to 80,000\u002Fmm3; and\n  * Hemoglobin must be ≥ 8 g\u002FdL. (Note: transfusions may be used to correct hemoglobin for patients experiencing anemia from therapy who otherwise would be eligible for the study.)\n  * Albumin greater than (\\>) 3.0 g\u002FdL.\n* The following criteria for evidence of adequate hepatic function performed within 28 days prior to study entry must be met:\n\n  * Total bilirubin less than or equal to (≤) 1.5 x ULN\n  * AST and ALT must be ≤ 3.0 x ULN for the lab. (Note: In patients with elevated ALT or AST, the values must be stable for at least 2 weeks and with no evidence of biliary obstruction on imaging.)\n* Creatinine must be ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 40mL\u002Fmin.\n* All prior chemotherapy toxicities (excluding alopecia, amenorrhea, and peripheral neuropathy) must be less than (\\\u003C) Grade 2 at the time study therapy is to begin unless AE(s) are clinically stable on supportive therapy.\n* Patients must have no evidence of opportunistic infections.\n* Patients of childbearing potential must have a negative pregnancy per institutional policies prior to receiving the first dose of study therapy.\n* Male and female patients with reproductive potential must agree to use accepted effective methods of contraception while receiving study therapy and for at least 180 days (6 months) after the completion of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.\n\nExclusion Criteria:\n\n* Colon cancer other than adenocarcinoma, e.g., sarcoma, lymphoma, carcinoid.\n* Patients with MSI-high (dMMR) tumors.\n* Use and\u002For receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, targeted therapy, biologic therapy, monoclonal anti-bodies) or radiation therapy within 4 weeks prior to receiving first dose of study therapy or associated with immune-mediated adverse events (imAEs) that were Grade ≥1 within 90 days prior to the first dose of study therapy or associated with toxicity that resulted in discontinuation of the immune-modulating agent.\n* History of active or latent tuberculosis (TB) infection. If the presence of TB (active or latent) is established, then treatment for TB must be completed according to local guidelines prior to the screening.\n* Active untreated or uncontrolled systemic fungal, bacterial, or viral infections, or active infection requiring systemic anti-infectious therapy.\n* Current or history of systemic autoimmune disease requiring systemic immunosuppressive therapy will not be allowed. Note: the following will not be exclusionary: 1) the presence of laboratory evidence of autoimmune disease (e.g., positive antinuclear antibody titer or lupus anticoagulant) without associated symptoms; 2) clinical evidence of vitiligo or other forms of depigmenting illness; 3) mild autoimmunity not impacting the function of major organs (e.g., controlled Hashimoto thyroiditis, limited psoriasis), Type I diabetes.\n* Patients will be excluded if they are on systemic steroid therapy that cannot be discontinued (except for the use of prednisone or equivalent \\\u003C0.125mg\u002Fkg\u002Fday as replacement therapy). Inhaled or topical steroids are permitted.\n* Receipt of live attenuated vaccination within 30 days prior to study entry.\n* Known active or chronic hepatitis B virus (HBV) or hepatitis C virus (HCB) infections.\n\nNote: Patients with a history of hepatitis C virus (HCV) infection must have been treated and with confirmation of cure, can be eligible.\n\n* History of allogeneic organ or bone marrow transplantation.\n* Any of the following cardiovascular conditions:\n\n  * Documented NYHA Class II, III or IV congestive heart failure,\n  * History of myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to starting study treatment\n  * Transient ischemic attack (TIA) or stroke within 1 year.\n  * History of myocarditis\n  * Troponin T (TnT) or troponin I (TnI) \\> 2x institutional ULN at baseline. Patients with TnT or TnI levels between \\> 1 to 2x ULN are permitted if repeat levels within 24 hours are ≤ 1x ULN. If TnT or TnI levels are \\> 1 to 2x ULN within 24 hours, the subject may undergo a cardiac evaluation and be considered for treatment by the investigator based on medical judgement in the patient's best interest.\n* Active, documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).\n* Major surgical procedure within 28 days prior to study entry.\n* Other malignancies: unless the patient is considered disease-free and has completed therapy for the malignancy greater than or equal to 36 months prior to study entry. Patients with the following cancers are eligible if diagnosed and definitively treated within the past 12 months: carcinoma in situ of the cervix, and basal cell and squamous cell carcinoma of the skin. Other in situ neoplasms will be reviewed by the Protocol Officer and\u002For Protocol Chair.\n* Psychiatric or addictive disorders or other conditions that in the opinion of the investigator would preclude the patient from meeting the study requirements or interfering with interpretation of study results.\n* Pregnancy or lactation at the time of study entry.\n* Use of any investigational agent within 28 days prior to the first dose of study therapy.","ALL","18 Years",{"count":21,"type":22},79,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment. Immunotherapeutic drugs (immunotherapies) act on different proteins on the surface of cells of the immune system and trigger the immune system to destroy cancer cells. The drugs being studied in NSABP FC-13 are cemiplimab, fianlimab, and REGN7075.",[28],"Colo-rectal Cancer","RECRUITING","2026-06-11",{"date":32,"type":33},"2026-06-12","ACTUAL",{"date":35,"type":33},"2026-04-17",{"date":37,"type":22},"2029-06-01",{"name":39,"class":40},"NSABP Foundation Inc","NETWORK",9,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":53,"conditions":54,"keywords":61,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100643245","prehabilitation-in-high-risk-oncologic-surgery-100643245","NCT07638410","Prehabilitation in High-risk Oncologic Surgery","SURG-236: Prehabilitation in High-risk Oncologic Surgery: A Prospective Cohort Study","Inclusion Criteria:\n\n* Evidence of probable or confirmed primary or recurrent malignant neoplasm of any stage\n* Planned to undergo neoadjuvant chemotherapy or chemoradiation\n* Eligible surgical candidate for one of the following procedures: pancreatectomy, gastrectomy, esophagectomy, cystectomy, low anterior resection, abdominoperineal resection, or cytoreductive surgery with heated intraperitoneal chemotherapy\n* Age greater than 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Ability to understand and willingness to sign a written informed consent form and Health Insurance Portability and Accountability Act (HIPAA) authorization document\n\nExclusion Criteria:\n\n* Unable to complete study requirements, such as attending a minimum of two visits for each specialty referral. This will be assessed at the final preoperative visit, at which time the participant may be discontinued from the study and replaced. Participants will not be excluded due to lack of insurance coverage for health psychology visits.\n* Does not proceed to surgery at an affiliated institution\n* Pregnant or breastfeeding",{"count":50,"type":22},180,[52],"NA","The goal of this clinical study is to learn whether a prehabilitation program can improve recovery after major abdominal surgery in adults with cancer who are receiving treatment before surgery. Prehabilitation is supportive care given before surgery to help patients prepare physically, nutritionally, and emotionally.\n\nThe main questions this study aims to answer are:\n\n1. Does prehabilitation reduce the number of participants who die or have serious complications within 30 days after surgery?\n2. Does prehabilitation improve physical strength and fitness, nutritional status, emotional well-being, and quality of life before surgery?\n3. Does prehabilitation affect the length of the hospital stay after surgery, the time it takes to start additional cancer treatment after surgery, or the ability to complete recommended additional treatment?\n\nParticipants will take part in a prehabilitation program during their treatment period before surgery. The program includes visits with physical therapy, nutrition, and health psychology. Participants will meet with each specialty at least twice before surgery. They will also complete questionnaires and tests that measure physical function, diet and weight, emotional well-being, and quality of life. After surgery, information about recovery and additional cancer treatment will be collected from medical records for up to 120 days.\n\nResearchers will compare the outcomes of participants who receive the prehabilitation program with outcomes from similar patients who previously received care at Fox Chase Cancer Center but did not participate in this study.",[55,28,56,57,58,59,60],"Pancreatic Cancer","Gastric Cancer","Esophageal Cancer","Bladder Cancer","Ovarian Cancer","Abdominal Surgery Complications",[62,63,64,65,66,67,68,69],"Prehabilitation","Preoperative Rehabilitation","Multimodal Prehabilitation","Major Abdominal Surgery","Oncologic Surgery","Neoadjuvant Therapy","Postoperative Complications","Cancer Surgery","NOT_YET_RECRUITING","2026-06-09",{"date":30,"type":33},{"date":74,"type":22},"2026-06-15",{"date":76,"type":22},"2030-03-15",{"name":78,"class":79},"Fox Chase Cancer Center","OTHER",{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100565656","the-aidpro-crc-trial-100565656","NCT06645015","The AIDPRO-CRC Trial","AI-Driven Personalized Perioperative Management in Colorectal Cancer: A Randomized Controlled Clinical Trial - The AIDPRO-CRC Trial","AIDPRO-CRC","Inclusion criteria - patients\n\nTo be eligible for study participation, the following criteria must be met:\n\n* Histologically confirmed diagnosis or strong clinical suspicion of first-time colon or rectal cancer, clinical stage I-IV.\n* Signed written informed consent obtained prior to any study-specific procedures.\n* Age ≥18 years at the time of consent.\n* Scheduled for potentially curative surgery as determined by a multidisciplinary team (MDT) conference.\n* Availability of all required input variables for the AI model not directly assessed by the surgeon (e.g., ASA score, WHO performance status).\n\nExclusion criteria - patients\n\nA patient will be excluded from the study if:\n\n• Surgery with curative intent is no longer planned despite previous eligibility.\n\nHealthcare Professionals Surgeons and other healthcare professionals involved in the use of the AI-based platform will be invited to participate in two sub-studies: a user satisfaction survey and a simulation-based study. Eligible personnel will be automatically invited upon registration as platform users.\n\nInclusion criteria - healthcare professionals\n\nTo be eligible to participate in the survey and simulation study, individuals must:\n\n* Be licensed medical doctors.\n* Be either board-certified specialists in surgical oncology or currently in training to become one.\n\nExclusion criteria - healthcare professionals There are no exclusion criteria for participation in the survey or simulation study.",{"count":89,"type":22},1200,[52],"The AIDPRO-CRC trial aims to improve outcomes for patients undergoing surgery for colorectal cancer by using artificial intelligence (AI) to assist surgeons in risk assessment. The trial will evaluate whether AI can help surgeons better predict the risk of complications and death, leading to improved care, fewer complications, and better use of healthcare resources.\n\nIn this nationwide, randomized clinical trial, participants will be divided into two groups. One group will have their risk assessed by a surgeon using standard clinical methods, while the other group will have their risk assessed by a surgeon using AI assistance. Based on the risk level, patients will receive varying levels of perioperative care. The AI-assisted risk assessment aims to tailor the treatment more precisely to each patient's individual needs, precisely allocating care to those who need it to more efficiently allocate heath system resources while having no deterioration in patient outcomes.\n\nThe primary hypothesis is that AI-assisted risk assessment will lead to more efficient and economic patient care without a deterioration in patient outcomes. The trial also aims to explore clinician satisfaction with the platform and its perceived effect. This is paired with a substudy exploring the variability of suggested treatment plans by clinicians with and without access to the MDT presentation platform.\n\nThe trial will include patients at seven hospitals across Denmark, involving patients diagnosed with colorectal cancer who are scheduled for curative surgery. All patients will receive standard treatment according to national guidelines, with the only difference being the modality of risk assessment. For the evaluation of the clinicians satisfactory with the device and the substudy of variability of suggested treatment plans, the trial will enroll clinicians using the device.\n\nThis study is a researcher-initiated, nationwide, randomized clinical trial involving patients diagnosed with colorectal cancer across eight hospitals in Denmark. Participants will be randomly assigned to one of two groups: AI-assisted risk assessment or standard surgeon-led assessment. The intervention focuses on optimizing perioperative care based on individual risk levels determined by either AI or the surgeon's clinical judgment.\n\nThe study builds on a successful pilot project (AID-SURG) that showed promising results in reducing complications, hospital stays, and readmissions.",[28],[62,94,95,96,97,98,99,100],"AI","Artificial Intelligence","Risk-estimation","perioperative","Post-operative complications","Risk-stratification","Algorithm","2026-05-28",{"date":103,"type":33},"2026-06-02",{"date":105,"type":33},"2025-10-24",{"date":107,"type":22},"2028-02-01",{"name":109,"class":79},"Zealand University Hospital",7,{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":119,"sex":18,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":138},"100638432","decision-counseling-and-follow-up-for-shield-patients-100638432","NCT07620535","Decision Counseling and Follow-up for Shield+ Patients","Decision Counseling and Follow-up (DCaF) for Shield+ Patients","DCaF","Inclusion Criteria:\n\n* Participant is 45-75 years old at the time of ShieldTM test order.\n* Participant has a valid Shield(+) test result.\n* Participant is willing and able to complete the informed consent process\n* Participant is able to complete the informed consent process and decision counseling session in English\n\nExclusion Criteria:\n\n* Participant is already enrolled in another Guardant Health, Inc. clinical study or has received a positive MCD result for a cancer type other than CRC.",true,"45 Years","75 Years",{"count":123,"type":22},350,"OBSERVATIONAL","Prospective, observational, minimal-risk study evaluating decision-making, decisional conflict, intention to undergo complete diagnostic evaluation (CDE), and colonoscopy completion after a positive Shield TM blood-based colorectal cancer screening test result.",[28],[28,128],"Screening","2026-05-27",{"date":103,"type":33},{"date":132,"type":22},"2026-06",{"date":134,"type":22},"2028-06",{"name":136,"class":137},"Guardant Health, Inc.","INDUSTRY",1,{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":147,"conditions":148,"keywords":152,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":138},"100463933","evaluation-of-single-port-sp-robotic-technology-in-colorectal-surgery-100463933","NCT05321134","Evaluation of SINGLE PORT (SP) Robotic Technology in Colorectal Surgery","Inclusion Criteria:\n\n* The subject is male or female, greater than or equal to 18 years of age. If female, the subject has a negative urine pregnancy test and is not lactating, or has not been of childbearing potential for at least 3 months prior to use of study product. To be considered to be not of childbearing potential, the subject must be postmenopausal for at least 2 years; have had a hysterectomy or bilateral tubal ligation, or be proven to be otherwise incapable of pregnancy. If of childbearing potential, the subject must have been practicing one of the following methods of contraception consistently for at least 1 month prior to study entry and agree to continue practicing it during the study: hormonal contraceptives, intrauterine device, spermicide and barrier, spouse\u002Fpartner sterility; or is practicing abstinence and agrees to continue abstinence or to start an acceptable method of contraception from the above list if sexual activity commences.\n* There is documentation of a colorectal diagnosis requiring operative interventions with clinical plans for a robotic operation.\n* For robotic transanal procedures, patients who would meet standard guidelines for a transanal procedures (T1N0 rectal adenocarcinoma, Precancerous adenomas, and localized neuroendocrine tumors) distal to 15 cm from the anal verge.\n* The subject is in good general health as evidenced by medical history and physical examination\n* The subject is able and willing to provide written informed consent.\n* The subject agrees to comply with the requirements of the protocol and complete study measures.\n* The subject has stable residence and telephone.\n\nExclusion Criteria:\n\n* The subject is child less than 18 years of age\n* The subject is a female who is pregnant or lactating\n* The subject falls under the American Society of Anesthesia Class IV (Patients with severe systemic disease that is a constant threat to life).\n* The subject falls under American Society of Anesthesia Class V (Moribund patients who is not expected to survive without the operation)\n* The subject has a history of clinically significant renal, hepatic, neurological, cardiac or chronic pulmonary disease that in the judgment of the investigator precludes participation.\n* The subject has advanced\u002F Stage IV cancer\n* The subject has received neo-adjuvant chemotherapy or radiation therapy\n* The subject requires an emergency operation.\n* The subject is unable to fully comprehend or consent to the study\n* The subject is unwilling to be available for follow-up assessments.",{"count":7,"type":22},[52],"Currently a multiport robotic surgery platform (Intuitive Xi) is widely available and used for colorectal surgery indications. A Single port platform (Intuitive SP) is FDA approved for Head and Neck and Urology but has not been widely used in colorectal surgery. This study seeks to evaluate the safe and effective use of the SP platform for colorectal surgery indications.",[28,149,150,151],"Rectal Prolapse","Colostomy Stoma","Colorectal Disorders",[153,154,155,156],"robotic surgery","colorectal surgery","single port","Intuitive SP platform","2026-05-26",{"date":159,"type":33},"2026-05-29",{"date":161,"type":33},"2022-04-28",{"date":163,"type":22},"2028-04",{"name":165,"class":79},"University of California, Davis",{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":177,"conditions":178,"keywords":185,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":206},"100599484","phase-1-a-first-in-human-study-of-alx2004-with-advanced-or-metastatic-selected-solid-tumors-100599484","NCT07085091","A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors","A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants With Advanced or Metastatic Select Solid Tumors","Inclusion Criteria:\n\n* Participants with locally advanced, recurrent or metastatic histologically confirmed HNSCC, NSCLC, ESCC, CRC; locally advanced or recurrent disease must not be amenable to resection with curative intent\n\n  1. Dose Escalation: Participants who have relapsed or progressed following prior anticancer therapy in the advanced\u002Fmetastatic setting and for whom no approved or standard therapy is available.\n  2. Dose Exploration and Dose Expansion: The following tumor-specific criteria also apply. These cohorts will include all or a subset of these tumors.\n\nHNSCC - Received no more than 3 prior lines of therapy in the advanced or metastatic setting\n\nNSCLC - For participants with a targetable molecular alteration: received appropriate standard targeted therapy and no more than 2 prior lines of systemic chemotherapy in the advanced\u002Fmetastatic setting. For participants without a targetable molecular alteration: received platinum-based chemotherapy and CPI (in combination or separately), and have received no more than 2 prior lines of systemic chemotherapy in the advanced\u002Fmetastatic setting\n\nESCC - Received no more than 3 prior lines of therapy in the advanced\u002Fmetastatic setting\n\nCRC - For participants with a targetable molecular alteration (including dMMR or MSI-H): Received appropriate standard therapy for the alteration, at least 2 prior lines of systemic chemotherapy, and no more than 4 prior lines of therapy in the advanced\u002Fmetastatic setting. For participants without a targetable molecule alteration: Received at least 2 prior lines of systemic chemotherapy (including an oxaliplatin-based chemotherapy), vascular endothelial growth factor (VEGF)-based therapy, and no more than 4 prior lines of therapy in the advanced\u002Fmetastatic setting.\n\n* Adequate Bone Marrow Function\n* Adequate Renal \\& Liver Function\n* Adequate Performance Status\n\nExclusion Criteria:\n\n* Participants with disease suitable for local therapy with curative intent.\n* Has a life expectancy of less than 3 months and\u002For has rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator\n* Prior treatment with any ADCs that have an active TOP1 inhibitor-based component",{"count":174,"type":22},170,[176],"PHASE1","A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors",[179,180,181,182,28,183,184],"NSCLC (Advanced Non-small Cell Lung Cancer)","HNSCC","CRC (Colorectal Cancer)","ESCC","Head and Neck Cancer","Esophageal Squamous Cell Carcinoma (ESCC)",[186,187,188,189,190,191,180,192,193,194,195,196],"ALX2004","EGFR","Solid Tumors","metastatic","Antibody Drug Conjugate","ADC","CRC","Lung","Non small cell lung cancer","esophageal","EGFR ADC","2026-05-11",{"date":199,"type":33},"2026-05-12",{"date":201,"type":33},"2025-08-18",{"date":203,"type":22},"2027-12",{"name":205,"class":137},"ALX Oncology Inc.",8,{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":18,"minAge":120,"maxAge":121,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":216,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":225,"leadSponsor":227,"locationsCount":138},"100619519","colorectal-cancer-screening-outreach-100619519","NCT07345676","Colorectal Cancer Screening Outreach","Optimizing Evidence-Based Interventions to Improve Colorectal Cancer Screening Adherence in Community Health Clinics","Inclusion Criteria:\n\n* Established adult medicine patient at Cornell Scott Hill health (defined as having a CSHH primary care doctor or \\>1 adult medicine visits in the last year).\n* Incomplete colorectal cancer screening test defined as an outstanding order for colonoscopy or stool-based CRC screening (e.g., fecal immunochemical test (FIT) or FIT-DNA testing), but no evidence of test completion at the time of randomization. Orders must have been placed between 90-180 days prior to randomization.\n\nOR\n\n* Abnormal stool-based test without follow-up, defined as an abnormal stool-based test result (e.g., positive FIT or FIT-DNA) with no completed diagnostic colonoscopy within 90 days of the result. Patients who meet this criterion will be included in a non randomized arm of the study.\n\nExclusion Criteria:\n\n* Because this is a pragmatic study of a behavioral intervention to improve colorectal cancer screening adherence, any participants who otherwise meet the inclusion criteria will not be excluded.",{"count":215,"type":22},2000,[52],"This is a 4 arm pragmatic trial to test a multicomponent intervention designed to improve adherence to colorectal cancer screening.",[28],[220],"Screening adherence","2026-04-28",{"date":223,"type":33},"2026-04-30",{"date":132,"type":22},{"date":226,"type":22},"2027-07",{"name":228,"class":79},"Yale University",{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":237,"conditions":238,"keywords":240,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":138},"100467334","clinicopathological-characteristics-of-colon-cancer-in-young-age-100467334","NCT05365412","Clinicopathological Characteristics of Colon Cancer in Young Age","Inclusion Criteria:\n\n* Patients treated after being diagnosed with colorectal cancer\n\nExclusion Criteria:\n\n* Patients under age of 18 years, or patients who cannot choose whether to participate or not\n* Patients who refuse to participate in the study",{"count":236,"type":22},1400,"A Study on the Characteristics of Colorectal Cancer by Age and sex.",[28,239],"Molecular Pathway Deregulation",[241,242,243],"colorectal cancer","prognosis","sex difference","2026-04-23",{"date":221,"type":33},{"date":247,"type":33},"2019-01-01",{"date":249,"type":22},"2026-12",{"name":251,"class":79},"Seoul National University Bundang Hospital",{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":121,"enrollmentInfo":259,"targetDuration":4,"studyType":23,"phases":261,"briefSummary":262,"conditions":263,"keywords":264,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":274,"locationsCount":138},"100632613","phase-2-fuliri-plus-targeted-therapy-for-first-line-conversion-therapy-of-colorectal-cancer-liver-metastases-100632613","NCT07515963","FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.","A Phase II Clinical Study of FULIRI Regimen Chemotherapy Combined With Targeted Therapy for First-line Conversion Treatment of Colorectal Cancer Liver Metastases.","Inclusion Criteria:\n\n\\- (1) Age 18-75 years; (2) Histologically confirmed colorectal adenocarcinoma; (3) Synchronous liver metastasis of colorectal cancer, or liver metastasis occurring after curative surgery for colorectal cancer, and no prior systemic anti-tumor treatment (including but not limited to systemic chemotherapy, molecular targeted therapy, immunotherapy, biological therapy, and other investigational drugs) after diagnosis of liver metastasis; (4) Liver metastasis deemed unresectable by MDT assessment, or potentially resectable but with a CRS score ≥3; (5) For patients who have received neoadjuvant or adjuvant therapy for colorectal cancer, the date of first diagnosis of liver metastasis must be at least 6 months after the last dose of neoadjuvant or adjuvant therapy; (6) At least one measurable target lesion on CT scan, assessable according to RECIST v1.1 criteria; (7) ECOG performance status 0-2; (8) Good organ function, without severe comorbidities of the heart, liver, lungs, kidneys, brain, etc.; (9) Blood routine: HGB ≥90 g\u002FL, WBC \\>3.5 × 10\\^9\u002FL (NEU ≥1.5 × 10\\^9\u002FL), PLT ≥90 × 10\\^9\u002FL; Liver function: ALT or AST ≤2.5 times the upper limit of normal (ULN); Bilirubin ≤1.5 × ULN; Renal function: serum creatinine ≤1.5 × ULN; (10) Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before starting the study medication and be willing to use a medically approved highly effective contraceptive method during the study and for 3 months after the last dose of study medication; male subjects with partners of childbearing potential must agree to use effective contraception during the study and for 3 months after the last dose of study medication.\n\n(11) The subject has given informed consent and signed the informed consent form, and is willing and able to comply with the planned visits, study treatment, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* (1) Pathological diagnosis reveals the presence of neuroendocrine tumor, squamous cell carcinoma, or adenosquamous carcinoma components; (2) Presence of conditions requiring emergency treatment, such as bowel obstruction, bowel perforation, or bleeding; (3) Presence of multiple metastases in sites other than the liver (excluding localized lung metastases (≤2) or localized retroperitoneal lymph node metastases, provided the investigator assesses that the patient has a chance of achieving NED status); (4) Patients with known microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) who are deemed suitable for immunotherapy with immune checkpoint inhibitors by the investigator; (5) Previous treatment with irinotecan; (6) Underweight (Body Mass Index \\[BMI\\] \\\u003C 18 kg\u002Fm2); (7) Concurrent or previous history of other malignancies besides cervical carcinoma in situ and basal cell carcinoma of the skin; (8) Concurrent severe infection or active pulmonary tuberculosis; (9) History of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation; (10) Patients with hepatitis B, if hepatitis B DNA exceeds 1000 copies\u002FmL, should be excluded; patients with hepatitis C, if hepatitis C RNA is positive, should be excluded; (11) Received surgery or other anti-tumor treatments (including chemotherapy, radiotherapy, investigational treatments, etc.) within 4 weeks prior to enrollment; (12) Concurrent severe gastrointestinal dysfunction (\\> Grade I according to NCI-CTCAE v5.0, such as intestinal inflammation or diarrhea); (13) Presence of conditions within the past 6 months that contraindicate targeted therapy, such as arterial embolism, severe bleeding, or bowel perforation (excluding bleeding caused by surgery); (14) Concurrent severe or uncontrolled systemic diseases, including but not limited to hypertension (systolic blood pressure consistently above 150 mmHg, diastolic blood pressure consistently above 95 mmHg), diabetes, heart disease, etc.; (15) Patients who cannot tolerate this study or who may be allergic to the medications used in this study; (16) Patients with cognitive impairment or co-existing severe mental disorders, who are judged by the investigator to have poor adherence to chemotherapy; or other situations deemed unsuitable for participation in clinical research by the investigator.",{"count":260,"type":22},24,[25],"This study is a single-center, prospective, randomized, single-arm phase II clinical trial designed to evaluate the safety and efficacy of FULIRI chemotherapy regimen combined with targeted therapy (bevacizumab\u002Fcetuximab) as first-line conversion therapy for colorectal cancer with liver metastases. Eligible patients with colorectal cancer and liver metastases, after signing informed consent, received FULIRI chemotherapy combined with bevacizumab\u002Fcetuximab targeted therapy. Efficacy was assessed after every four treatment cycles, followed by multidisciplinary team (MDT) discussion regarding potential surgical resection, ablation, or stereotactic radiotherapy. The primary endpoint was the objective response rate (ORR), and secondary endpoints included: disease control rate (DCR), R0 resection rate of liver metastases, progression-free survival (PFS), 3-year\u002F5-year survival rates, and the incidence of acute toxicities of any grade and grades 3\u002F4.",[28],[265,266,267],"Colorectal cancer","Liver metastasis","FULIRI","2026-03-30",{"date":270,"type":33},"2026-04-07",{"date":272,"type":22},"2026-06-01",{"date":107,"type":22},{"name":275,"class":79},"Zhongnan Hospital",{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":119,"sex":18,"minAge":120,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":286,"conditions":287,"keywords":288,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":298},"100583725","shield-post-approval-study-protocol-100583725","NCT06880055","Shield Post-Approval Study Protocol","SOLAR","Inclusion Criteria:\n\n1. Subjects aged 45-81 years at time of consent\n2. Intending to undergo a standard of care Shield test\n3. Considered by a physician or healthcare provider as being of 'average risk' for CRC; 'Average-risk' individuals in the context of CRC screening are defined as those who do not have symptoms of CRC and do not have increased risk factors for the disease (i.e., prior diagnosis of CRC, adenomatous polyps, or inflammatory bowel disease; family history of CRC or known hereditary predisposition to CRC).\n4. Subject agrees to comply with study procedures and associated standard of care assessments.\n\nExclusion Criteria:\n\n1. Undergoing colonoscopy for investigation of symptoms\n2. Personal history of colorectal cancer (CRC), adenomas, or other related cancers\n3. Family history of CRC, defined as having one or more first-degree relative (parent, sibling, or child) diagnosed with CRC at any age\n4. Positive result on another colorectal cancer screening method within the last six months, or:\n\n   * 12 months for fecal occult blood test (FOBT) or fecal immunochemical test (FIT)\n   * 36 months for FIT-DNA test\n5. Personal history of any of the following high-risk conditions for colorectal cancer:\n\n   * Inflammatory Bowel Disease (IBD), including chronic ulcerative colitis (CUC) and Crohn's disease\n   * Familial adenomatous polyposis (FAP)\n   * Other hereditary cancer syndromes including but not limited to:\n\n     * Hereditary non-polyposis colorectal cancer syndrome (HNPCC) or \"Lynch Syndrome\", Peutz- Jeghers Syndrome, MUTYH Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis\n6. Positive Shield test result within the previous 3 years\n7. History of any malignancy (patients who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study)\n8. Known diagnosis of inflammatory bowel disease\n9. Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs (DMARDs)\n10. Any major physical trauma (e.g., disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent\n11. Known medical condition which, in the opinion of the Investigator, should preclude enrollment into the study\n12. Participation in a clinical research study in which an experimental medication has been administered or may be administered within the 30 days leading up to providing informed consent or may be administered through the time of colonoscopy","81 Years",{"count":285,"type":22},3375,"The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC using colonoscopy as the reference method.",[28],[128,289],"Shield","2026-03-18",{"date":292,"type":33},"2026-03-19",{"date":294,"type":33},"2025-07-14",{"date":296,"type":22},"2030-12-01",{"name":136,"class":137},56,{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":138},"100629058","a-study-of-biological-genetic-and-constitutional-factors-and-non-invasive-monitoring-to-assess-personal-cancer-risks-100629058","NCT07469709","A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks","A Platform for Assessing Personal Risk of Developing or Recurring of Cancer: Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring of Subclinical Recurrences With Therapeutic Impact","PRO-ACTIVE","Inclusion Criteria:\n\n* Age \\>18 years;\n* Patients with breast cancer, including patients who meet the AIOM criteria for eligibility for BRCA testing and patients with lobular breast cancer;\n* Patients with radically resected colon cancer, including patients with stage III colon cancer and vascular invasion;\n* Patients with ovarian carcinomas;\n* Patients with metastatic melanoma;\n* Patients with stage IIB and IIIA non-small cell lung cancer.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years;\n* Unwillingness or inability to give informed consent",{"count":308,"type":22},850,"The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the disease. It starts with risk prediction and leads to early diagnosis of the disease or recurrence in the subclinical phase.\n\nThe PRO-ACTIVE study includes the following activities:\n\n* WP1: Integrated DNA-RNA approach for the identification of hereditary markers of predisposition to tumors\n* WP2: Global biological and molecular analysis of the host and tumor for the prevention and monitoring of recurrences\n* WP3: Analysis of the immunological status for the diagnosis of primary prevention and relapses in correlation to genetic and environmental factors\n* WP4: Study of the tumor microenvironment for recurrence prediction",[311,28,59,312,313],"Breast Cancer","Melanoma (Skin Cancer)","Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)","2026-03-09",{"date":316,"type":33},"2026-03-13",{"date":318,"type":33},"2024-02-01",{"date":320,"type":22},"2027-12-31",{"name":322,"class":79},"Fondazione del Piemonte per l'Oncologia",{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":119,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":360},"100627590","liquid-biopsy-and-machine-learning-for-early-colorectal-cancer-adenomas-lynch-cancers-and-residual-disease-detection-100627590","NCT07450612","Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection","BEACON","Inclusion Criteria:\n\n* All individuals included in the study need to have had a colonoscopy at the time of blood sampling.\n* Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Received standard pathological and endoscopic diagnosis and assessment for cohort assignment\n\nExclusion Criteria:\n\n* Lack of informed consent\n* Inflammatory bowel disease",{"count":89,"type":22},"This is an multicenter study that will test the diagnostic accuracy of a blood test (i.e., a liquid biopsy) for the diagnosis of colorectal cancer (CRC), advanced adenomas (AAs), as well as Lynch-syndrome associated cancers. Additionally, a pre-planned analysis will evaluate the use of this liquid biopsy as a tool for molecular residual disease monitoring purposes.",[333,334,335,336,28,337,338,339,340,341,342,343,344,345,346,347,348,349,350],"Colorectal Cancer","Adenoma Colon","Adenoma Colon Polyp","Colon Adenoma","Colon Disease","Colon Neoplasm","Lynch Syndrome","Lynch Syndrome I","Lynch Syndrome II","Lynch Syndrome I (Site-specific Colonic Cancer)","LYN Gene Mutation","Mismatch Repair Deficiency","Mismatch Repair Gene Mutation","MLH1 Gene Mutation","MSH2 Gene Mutation","MSH6 Gene Mutation","PMS2 Gene Mutation","EPCAM Gene Mutation","2026-02-27",{"date":353,"type":33},"2026-03-04",{"date":355,"type":33},"2024-01-01",{"date":357,"type":22},"2031-08-15",{"name":359,"class":79},"San Raffaele University",4,{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":23,"phases":370,"briefSummary":371,"conditions":372,"keywords":376,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":110},"100604110","phase-1-phase-12-dose-finding-safety-and-pk-study-in-advanced-refractory-solid-tumors-100604110","NCT07145255","Phase 1\u002F2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors","A Multicenter, Open-label Phase 1\u002F2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors","Inclusion Criteria: Patients are eligible to be included in the study only if all of the following criteria apply:\n\n1. Provide written consent on an informed consent form (ICF), approved by an Institutional Review Board (IRB)\u002FIndependent Ethics Committee (IEC), prior to any study-specific evaluation. Patients should have the ability to read and understand the ICF, ask for any clarifications from the study staff, and be able to comply with all planned study procedures.\n2. 18 years of age or older at the time of informed consent.\n3. Female patients must be at least 2 years postmenopausal (defined as 2 years without menses), surgically sterile (at least 6 months prior to dosing; must be documented) or patients of childbearing potential under the following conditions:\n\n   * Must be nonlactating and have a negative serum (preferred) or urine pregnancy test results within 72 hours prior to the first dose of MBRC-201.\n   * Must agree not to try to become pregnant during the study and for at least 6 months after the final dose of MBRC-201\n   * Must agree to practice effective contraception (must agree to use 2 forms of contraception, 1 of which must be a barrier method) and willing to continue to use effective contraception for the duration of study participation and for 6 months after the final dose of study drug.\n4. Male patients whose partners are of childbearing potential must agree to use effective contraception (must agree to use 2 forms of contraception, 1 of which must be a barrier method) (Section 10.4) for the duration of study participation and for 6 months after the final dose of study drug.\n5. Have a histologic or cytologic diagnosis of malignant solid tumor for which there are no standard-of-care treatment options known to confer a clinical benefit or for which the patient is ineligible or declines (except for Phase 1b-Cohort A).\n\n   A. For Phase 1a dose escalation: Patients must have one of the following tumor types:\n\n   i. mCRPC, breast cancer (TNBC, HR+\u002FHER2-negative or HER2-low, HR-\u002FHER2+), CRC, NSCLC, or PDAC\n\n   B. For Phase 1b: Patients must have one of the following tumor types:\n\n   i. Cohort A: Histologic or cytologic diagnosis of mCRPC (with confirmed adenocarcinoma histology) refractory to standard treatment.\n\n   Patients must have had prior exposure to at least one novel AR-targeted therapy (e.g., abiraterone acetate, enzalutamide, apalutamide, darolutamide). Prior taxane or lutetium Lu 177 vipivotide tetraxetan is acceptable but not required.\n\n   ii. Cohort B: Histologic or cytologic diagnosis of advanced metastatic NSCLC refractory to standard treatment.\n\n   iii. Cohort C: Histologic or cytologic diagnosis of advanced metastatic breast cancer (TNBC, HR+\u002FHER2-negative or HER2-low, HR-\u002FHER2+) refractory to standard treatment.\n\n   iv. Cohort D: Histologic or cytologic diagnosis of advanced metastatic CRC, PDAC refractory to standard treatment. The Sponsor may add or remove specific tumor indications based on emerging, real-time study results.\n6. Availability of a tumor tissue sample (formalin-fixed paraffin-embedded \\[FFPE\\]) must be confirmed if feasible. Patients without tumor sample may be eligible with medical monitor approval. Tumor biopsies are not required and should not be performed to assess eligibility.\n7. For Dose Escalation (Phase 1a), patients may have evaluable disease or measurable disease according to Response Evaluation Criteria in Solid Tumor (RECIST) v1.1. For both Dose Expansion (Phase 1b) and Phase 2, patients must have measurable disease according to RECIST v1.1\n8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n9. Life expectancy ≥ 3 months\n10. Patient must have adequate organ and marrow function as defined below.\n\n    * Absolute neutrophil count (ANC) ≥ 1500\u002FuL\n    * Hemoglobin (Hgb) ≥ 9 g\u002FdL\n    * Platelet count ≥ 100,000\u002FuL\n    * International normalized ratio (INR) \\\u003C 1.5 (or ≤ 3.0 if on therapeutic anticoagulation)\n    * Estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin by the CKD-EPI or similar equation or as measured by 24-hour urine collection\n    * Total bilirubin ≤ 1.5 × ULN \\[or ≤ 3-times ULN for patients with Gilbert's disease or documented hepatic tumor involvement\\]\n    * ALT and AST ≤ 3 × ULN \\[or ≤ 5-times ULN for patients with documented hepatic tumor involvement\\]\n\nExclusion Criteria: Patients are excluded from the study if any of the following criteria apply:\n\n1. History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Allowed exceptions are patients with:\n\n   1. Non-melanoma skin cancer considered completely cured;\n   2. Localized prostate cancer treated with curative intent with no evidence of progression;\n   3. Low-risk or very low-risk (per standard clinical guidelines) localized prostate cancer under active surveillance without immediate intent to treat;\n   4. Malignancy that is otherwise considered cured with minimal risk of recurrence.\n2. Known or suspected sensitivity to any of the ingredients of the investigational product MBRC-201.\n3. Active cerebral\u002Fmeningeal disease related to the underlying malignancy. Patients with a history of cerebral\u002Fmeningeal disease related to the underlying malignancy are allowed if prior central nervous system disease has been treated and the patient is clinically stable. (defined as not having received steroid treatment for symptoms related to cerebral\u002Fmeningeal disease for at least 2 weeks prior to the first dose of study drug and with no ongoing related AEs).\n4. Any uncontrolled viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study drug, unless deemed not clinically significant by the investigator (e.g., onychomycosis). Routine antimicrobial prophylaxis is permitted.\n5. Active or symptomatic viral hepatitis, including patients with active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months). Patients who have been treated for hepatitis C infection or who have spontaneously recovered are permitted.\n6. Patients with HIV infection with 1 or more of the following:\n\n   * Acquired immunodeficiency syndrome (AIDs)-defining opportunistic infection within 6 months of the start of screening\n   * A change in antiretroviral therapy within 3 months of the start of screening and viral load \\> 500 copies\u002FmL\n   * Receiving antiretroviral therapy that may interfere with study drug\n   * CD4 count \\\u003C 350 at screening\n7. Thromboembolic events and\u002For bleeding disorders ≤ 14 days (e.g., venous thromboembolism \\[VTE\\] or pulmonary embolism \\[or PE\\]) prior to the first dose of study drug\n8. Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug\n9. A baseline QT (time from the beginning of the Q wave to the end of the T wave) interval as corrected by Fridericia's formula (QTcF) \\> 470 msec or patients with risk factors for Torsades de pointes\n10. Uncontrolled Inflammatory Bowel Disease (IBD)\n11. A history of (non-infectious) ILD\u002Fpneumonitis requiring steroid therapy, or active ILD\u002Fpneumonitis, or clinically suspected ILD\u002Fpneumonitis that cannot be ruled out by imaging at screening\n12. Uncontrolled autoimmune disease or syndrome\n13. Active ocular surface disease at screening, including confluent superficial keratitis, cornea epithelial defect, corneal ulcer or stromal opacity or any components of the ophthalmologic history which, in the investigator's opinion, may place the patient at significant risk. Cataracts alone are not an exclusion criterion.\n14. Any anticancer therapy within 14 days prior to the first dose of study drug, including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy, radiotherapy, or any other agents to treat cancer (anti-hormonal therapy given for advanced prostate cancer or as adjuvant therapy for early stage, HR positive breast cancer is not considered cancer therapy for the purpose of this protocol).\n15. Use of any investigational drug within 14 days prior to the first dose of study drug.\n16. For Phase 1b and Phase 2: prior treatment with an ADC with a camptothecin (CPT) payload, such as Enhertu (trastuzumab deruxtecan), Datroway (datopotamab deruxtecan), or Trodelvy (sacituzumab govitecan). Prior treatment with irinotecan and other non-ADC topoisomerase inhibitors is allowed in all phases of the study.\n17. Current use of any prohibited concomitant medication(s).\n18. Major surgery within 28 days prior to first dose of study drug.\n19. Patients who have not recovered from AEs due to prior anticancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia\n20. Any medical, psychiatric, addictive, or other kind of disorder which compromises the ability of the patient to give written informed consent and\u002For to comply with procedures.\n21. Condition or situation which, based on Investigator or Sponsor assessment, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study.\n22. Other serious underlying medical condition that would impair the patient's ability to receive or tolerate the planned treatment and follow-up",{"count":369,"type":22},150,[176,25],"This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.",[373,311,28,374,375],"Prostate Cancer Castration-resistant Prostate Cancer","Lung Cancer (Non-Small Cell)","Pancreas Cancer, Duct Cell Adenocarcinoma",[191,377,378,241,379,380],"prostate cancer","breast cancer","non-small cell lung cancer","MBrace","2026-02-15",{"date":383,"type":33},"2026-02-17",{"date":385,"type":33},"2025-09-03",{"date":387,"type":22},"2029-12-30",{"name":389,"class":137},"MBrace Therapeutics",{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":119,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":23,"phases":400,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":405,"completionDateStruct":406,"leadSponsor":408,"locationsCount":138},"100624780","serum-talin-1-and-cripto-1-in-colorectal-cancer-100624780","NCT07414082","Serum Talin-1 and Cripto-1 in Colorectal Cancer","Evaluating Serum Talin-1 and Cripto-1 as Diagnostic Biomarkers in Colorectal Cancer","Talin-1\u002FCR-1","Inclusion Criteria:\n\n* Age \\>18 years Old.\n* Patients of both sexes who met the clinical diagnostic criteria of colorectal cancer (change in bowel habit, absolute or recurrent constipation, rectal bleeding, significant weight loss or intestinal obstruction)\n* Patients diagnosed with colorectal cancer by imaging and histopathology\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old.\n* Patients with past history of chemotherapy or surgical excision of tumor\n* Patients with familial adenomatous polyposis\n* Patients with hereditary non-polyposis colorectal cancer\n* Patients with inflammatory bowel disease\n* patients with other types of tumors",{"count":399,"type":22},70,[52],"The goals of this study are\n\n* To evaluate the clinical utility of Talin-1 and Cripto-1 measurement in colorectal cancer patients in comparison with healthy controls.\n* To Compare the diagnostic significance of serum Talin-1 and Cripto-1 with traditional serum biomarker CEA",[28],"2026-02-12",{"date":383,"type":33},{"date":268,"type":22},{"date":407,"type":22},"2029-12-31",{"name":409,"class":79},"Assiut University",{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":18,"minAge":418,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":23,"phases":421,"briefSummary":423,"conditions":424,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":138},"100559381","phase-3-stereotactic-ablative-radiotherapy-sabr-for-the-treatment-of-patients-with-metastatic-cancer-id-comet-trial-100559381","NCT06563388","Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial","(ID-COMET) A Randomized Phase III Trial of Immediate Versus Six-Month Delayed Comprehensive Treatment of 1-10 Oligometastatic Tumors With or Without Synchronous Primary","ID-COMET","Inclusion Criteria:\n\n* Age 1 year or older.\n* Willing to provide informed consent.\n* ECOG ≤ 3.\n* Life expectancy \\> 6 months.\n* Trials 1-3: Histologically confirmed lung, prostate or colorectal malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.\n* Trial 4: Any malignancy with metastasis. Participants with liquid tumors are eligible provided they have biopsy confirmed refractory disease and are eligible for salvage radiotherapy.\n* Newly diagnosed metastatic (1-10 sites)patients for Trials 1-3. Previously diagnosed metastatic patients (1-10 sites or oligoprogression in 5 or fewer sites with no limit on total number for Trial 4.\n* Restaging completed within 12 (+\u002F- 4) weeks prior to randomization.\n\n  * For patients receiving thoracic radiotherapy, the enrolling physician must confirm there are no computed tomography (CT) changes suggestive of fibrotic interstitial lung disease (ILD) (i.e., reticular changes, traction bronchiectasis, or honeycombing) reported on any prior CT scans. If any are present, the patient must be assessed by a respirologist to rule out ILD prior to enrollment.\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry.\n\nShould a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n\n* Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure.\n\nExclusion Criteria:\n\n* . Participants who have no option for standard systemic therapy or refuse systemic therapy.\n* Participants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier.\n* Serious medical comorbidities precluding radiotherapy. These include ILD in patients requiring thoracic radiation, Crohn's disease in patients where the gastrointestinal (GI tract will receive radiotherapy, or ulcerative colitis where the bowel will receive radiotherapy and connective tissue disorders such as lupus or scleroderma.\n* For patients with liver metastases, moderate\u002Fsevere liver dysfunction (Child Pugh B or C); please see the Child-Pugh score calculator.\n* Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein. For patients treated with radiation previously, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed in Appendix E. All such cases must be discussed with the PI or Co-I .\n\n  * Malignant pleural effusion.\n* Inability to treat all sites of disease.\n\n  * Metastatic disease that invades any of the following: GI tract (including esophagus, stomach, small or large bowel) or skin.\n  * Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.\n  * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n  * Pregnant or nursing female participants.","1 Year",{"count":420,"type":22},800,[422],"PHASE3","This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers",[425,426,28,427],"Oligometastasis","Lung Cancer","Prostate Cancer","2026-02-02",{"date":430,"type":33},"2026-02-04",{"date":432,"type":33},"2024-09-18",{"date":434,"type":22},"2032-09-18",{"name":436,"class":79},"Roswell Park Cancer Institute",{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":119,"sex":18,"minAge":444,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":447,"conditions":448,"keywords":449,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":138},"100596524","evaluation-of-the-natera-colorectal-cancer-screening-test-in-an-average-risk-population-find-crc-100596524","NCT07046585","Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)","FIND-CRC","Inclusion Criteria:\n\n1. Signed informed consent.\n2. 40 years of age or older at the time of consent.\n3. Planning or intending to undergo a standard of care colonoscopy.\n4. Able to tolerate venipuncture for research draw(s).\n5. Able and willing to provide blood samples within the 120 days prior to a standard-of-care pre-bowel preparation procedure and colonoscopy procedure.\n6. Willing and able to comply with the study visit schedule and study requirements.\n\nExclusion Criteria:\n\n1. Any prior history of any kind of malignancy (exception: participants who have undergone surgical removal of skin squamous cell or basal cell cancers may be enrolled, provided the procedure was completed at least 12 months prior to consent for the study).\n2. Had a complete colonoscopy with adequate bowel preparation in the previous nine (9) years.\n3. Undergoing diagnostic colonoscopy for the investigation of symptoms.\n4. Up to date with colorectal cancer screening from any non-invasive test.\n5. Precancerous findings on most recent colonoscopy.\n6. Had a prior colorectal resection for any reason other than sigmoid diverticular disease.\n7. Known personal history of any of the following high-risk conditions:\n\n7a. Inflammatory bowel disease. 7b. Known hereditary condition that would increase risk of colorectal cancer (example Lynch Syndrome).","40 Years",{"count":446,"type":22},25000,"The FIND-CRC study is a prospective collection of samples and data from participants who are at average risk of developing colorectal cancer (CRC). Collected samples and data will be analyzed to evaluate the clinical performance of the Natera CRC Screening Test.",[28],[241,450,451],"colon cancer","early cancer detection","2025-12-11",{"date":454,"type":33},"2025-12-12",{"date":456,"type":33},"2025-05-30",{"date":458,"type":22},"2033-09-30",{"name":460,"class":137},"Natera, Inc.",{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":119,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":23,"phases":470,"briefSummary":471,"conditions":472,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":138},"100559172","compare-the-patient-satisfaction-and-effectiveness-after-novel-application-based-or-conventional-health-education-of-bowel-preparation-for-colonoscopy-100559172","NCT06560671","Compare the Patient Satisfaction and Effectiveness After Novel Application-based or Conventional Health Education of Bowel Preparation for Colonoscopy","Compare the Patient Satisfaction and Effectiveness After Novel Application-based or Conventional Health Education of Bowel Preparation for Colonoscopy-- Randomized Controlled Trial","Inclusion Criteria:\n\n* adults planned to accept colonoscopy exam\n\nExclusion Criteria:\n\n* can't accept health education or refuse follow-up",{"count":469,"type":22},252,[52],"Colorectal cancer is the cancer with highest incidence in Taiwan. The disease itself and subsequent treatment cause huge impact on the physical, psychological, and spiritual parts and social role of a patient. Early diagnosis of colorectal cancer and precancerous lesions is possible. Early treatment can reduce the impact on quality of life and economics.\n\nColonoscopy is an important tool for diagnosis of colorectal proliferative lesions. Qualified bowel preparation can enhance sensitivity and reduce false negative of the colonoscopy. However, multiple factors influence the quality of bowel preparation. This study aims to investigate whether the animation video and game-based health education is more effective and satisfying than conventional health education, and to explore the difference of knowledge dissemination and quality of bowel preparation between novel and conventional methods.\n\nThis study is a randomized controlled trial and uses structural questionnaire for study participants. Before the main study, the investigators will consult professors' opinions to adjust and enhance validity of the questionnaire, and the investigators will perform pretest to calculate its reliability. The investigators will enroll participants at the out-patient-department and the health management center. Questionnaires may be completed by on-site paper or phone with internet resources. The main participants of this study are adults aged 18 and more, and planned to receive colonoscopy. The questionnaires investigate the spent time, patient satisfaction, knowledge of bowel preparation and results of colonoscopy of different approaches of health education. Multiple linear regression will be applied to calculate the possible significance difference between two kinds of health education.\n\nThe investigators expect this study (1) to explore whether novel health education enhances patient satisfaction (2) to investigate the efficiency of novel health education, and (3) to compare the effect of knowledge dissemination and quality of bowel preparation between experimental and control groups. This study will develop the model of health education to facilitate holistic health care.",[28,473],"Colon Lesion","2025-11-17",{"date":476,"type":33},"2025-11-20",{"date":478,"type":33},"2024-08-01",{"date":480,"type":22},"2026-03-31",{"name":482,"class":79},"National Taiwan University Hospital",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":119,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":489,"targetDuration":4,"studyType":23,"phases":491,"briefSummary":492,"conditions":493,"keywords":494,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":512,"locationsCount":360},"100479549","eliminating-barriers-to-colorectal-cancer-screening-using-rapid-cycle-testing-a-pilot-study-100479549","NCT05524428","Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study","Inclusion Criteria:\n\n* Staff members at partnering sites (see locations) who are administrative leaders, population health managers, data analysts, quality improvement staff, nurses, nurse managers, practice managers, medical assistants, and providers.\n* Staff members at partnering sites ages 18+.\n\nExclusion Criteria:\n\n* Staff members that are not involved in CRC screening practices at CHCs.",{"count":490,"type":22},2,[52],"The investigators will use a mixed methods study i.e. focus groups involving CHC staff as well as quantitative study which involves analyzing data that is available from the EHR and DRVS population management platform.",[28],[241,495,496,497,498,499,500,501,502,503,504,505],"cancer","screening","implementation science","health equity","cancer equity","healthcare access","minority health","early detection","public health","health justice","rapid testing","2025-11-12",{"date":508,"type":33},"2025-11-14",{"date":510,"type":33},"2023-03-24",{"date":249,"type":22},{"name":513,"class":79},"Massachusetts General Hospital",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":23,"phases":523,"briefSummary":524,"conditions":525,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":138},"100606681","phase-2-a-study-to-characterize-encorafenib-plus-cetuximab-as-rechallenge-treatment-for-braf-v600e-mutant-metastatic-colorectal-cancer-patients-after-previous-therapy-with-braf-inhibitors-based-combinations-100606681","NCT07178717","A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations","A Phase 2, Single-Arm Study of Encorafenib Plus Cetuximab as Rechallenge Treatment of BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations: the RefIsh Trial","REFISH","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Age ≥18 years at the time of informed consent.\n3. Histologically- or cytologically confirmed mCRC that is metastatic.\n4. Presence of confirmed BRAF V600E mutation.\n5. Eligible to receive cetuximab and encorafenib per locally approved label with regard to tumor RAS status.\n6. Patients must be previously treated with at least 2 prior regimens for metastatic disease and had demonstrated progressive disease or intolerance to their last regimen. Prior standard chemotherapy must include the following agents: fluoropyrimidine in monotherapy or in combination with irinotecan and\u002For oxaliplatin with or without anti-VEGF. Combination of chemotherapy with BRAF inhibitor-containing regimen is also permitted.\n7. Patients must have received BRAF inhibitor plus anti-EGFR combinations (including but not limited to MEK or ERK inhibitors or chemotherapy) treatment for ≥ 4 months. Patients must have had complete response, partial response or stable disease \\>6 months during the BRAF inhibitor-based treatment.\n8. Patients at study enrollment should have at least 4 months interval since the last administration of BRAF inhibitors.\n9. Life expectancy \\>12 weeks, as determined by the investigator.\n10. Patients must have progressed during or within 6 months of the last chemotherapy regimen \\> Patients who received adjuvant\u002Fneoadjuvant chemotherapy and had recurrence during or within 6 months of completion of the adjuvant\u002Fneoadjuvant chemotherapy are permitted to count the adjuvant\u002Fneoadjuvant therapy as one regimen for advanced disease.\n11. Measurable disease according to RECIST v1.1.\n12. ECOG performance status 0-1.\n13. Adequate bone marrow function characterized by the following at screening:\n\n    1. Absolute neutrophil count (ANC) ≥1.5 x 10\\^9\u002FL.\n    2. Platelets ≥100 x 10\\^9\u002FL.\n    3. Hemoglobin ≥9.0 g\u002FdL (with or without blood transfusions).\n14. Adequate hepatic and renal function characterized by the following at screening:\n\n    1. Serum total bilirubin ≤1.5 x upper limit of normal (ULN) and \\\u003C2 mg\u002FdL. Note: Total bilirubin \\>1.5 x ULN is allowed if direct (conjugated) ≤1.5 x ULN and indirect (unconjugated) bilirubin is ≤4.25 x ULN.\n\n       Note: Participants with hyperbilirubinemia due to non-hepatic cause (e.g., hemolysis, hematoma) may be enrolled following discussion and agreement with the Sponsor medical monitor.\n    2. Alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) ≤2.5 x ULN, or ≤5 x ULN in the presence of liver metastases.\n    3. Adequate renal function defined by an estimated creatinine clearance ≥50 mL\u002Fmin according to the Cockcroft Gault formula or by 24-hour urine collection for creatinine clearance, or according to local institutional standard method.\n    4. Protein \\\u003C 2+ on dipstick urinalysis or ≤ 1.0 g in a 24-hour urine collection. All patients with ≥2+ protein on dipstick urinalysis at baseline must undergo a 24-hour urine collection for protein.\n    5. Adequate electrolytes, defined as serum potassium and magnesium levels within institutional normal limits.\n\n    Note: Replacement treatment to achieve adequate electrolytes will be allowed.\n15. Adequate cardiac function characterized by the following at screening:\n\n    • Mean triplicate QT interval corrected for heart rate using Fridericia's formula (QTcF) value ≤480 msec.\n16. Able to take oral medications.\n17. Highly effective contraception for both male and female subjects if the risk of conception exists during and at least up to 2 months after the last study medication.\n\nExclusion Criteria:\n\n1. Treatment with another investigational drug or participation in another investigational study at enrolment or within 30 days prior to enrollment.\n2. Patient unable to comply with the study protocol owing to psychological, social (lack of social support or social exclusion) or geographical reasons.\n3. Patient is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study.\n4. Known history of chronic pancreatitis.\n5. Tumors with microsatellite instability or mismatch repair deficiency if they have not received a PD1\u002FPDL1 inhibitor-based treatment, unless medical contraindication.\n6. History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12 months before the enrollment in the study.\n7. Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following:\n\n   1. History of acute myocardial infarction, acute coronary syndromes (including unstable angina, coronary artery bypass graft \\[CABG\\], coronary angioplasty or stenting) ≤ 6 months prior to start of study treatment.\n   2. Symptomatic congestive heart failure (i.e., Grade 2 or higher), history or current evidence of clinically significant cardiac arrhythmia and\u002For conduction abnormality ≤ 6 months prior to start of study treatment, except atrial fibrillation and paroxysmal supraventricular tachycardia.\n8. Impaired hepatic function, defined as Child-Pugh class B or C.\n9. Known history of human immunodeficiency virus (HIV), active hepatitis B virus (HBV) infection or active hepatitis C virus (HCV) infection. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Patients with past exposure to HBV are also eligible for the study provided they are negative for HBV DNA.\n10. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Subjects with clinically inactive brain metastases may be included in the study.\n\n    Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and the enrollment in the study.\n11. Subjects with leptomeningeal carcinomatosis.\n12. Impaired gastrointestinal (GI) function or disease that may significantly alter the absorption of encorafenib (e.g., ulcerative diseases, uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption).\n13. Knowledge of any other disease or medication that may interfere with study treatment.\n14. Presence of any contraindication with regard to the study drugs as specified in the corresponding SmPCs.\n15. Patients who achieved progression disease as best response while receiving BRAF inhibitor previously.",{"count":7,"type":22},[25],"This is an open-label, unicentre, single-arm Phase 2 study of encorafenib and cetuximab as rechallenge treatment in patients with BRAF V600E-mutant metastatic colorectal cancer after previous therapy with BRAF inhibitors-based combinations.\n\nThe study aims to evaluate the antitumor activity of encorafenib plus cetuximab as a rechallenge strategy measured by progression-free survival rate at 4 months.\n\nEligible patients (a total of 25) will receive encorafenib 300 mg (four 75 mg capsules) once daily (q.d) in 28-day cycles plus intravenous cetuximab at 500 mg\u002Fm2 every 2 weeks (Q2W). Treatment will be administered until progression, unacceptable toxicity, patient request, physician's decision or subsequent anticancer therapy.",[28],"2025-09-10",{"date":528,"type":33},"2025-09-17",{"date":530,"type":22},"2025-10",{"date":532,"type":22},"2028-08",{"name":534,"class":79},"Vall d'Hebron Institute of Oncology",{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":541,"enrollmentInfo":542,"targetDuration":4,"studyType":23,"phases":543,"briefSummary":544,"conditions":545,"keywords":547,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":558,"locationsCount":138},"100585712","the-effect-of-the-training-program-given-to-permanent-colostomy-patients-on-self-efficacy-100585712","NCT06905925","The Effect of the Training Program Given to Permanent Colostomy Patients on Self-efficacy","Inclusion Criteria:\n\n* • Patients scheduled for permanent colostomy following colorectal surgery,\n\n  * Aged 18 years and older,\n  * Conscious, with orientation to person, time, and place,\n  * Able to speak Turkish,\n  * Without auditory or visual impairments,\n  * Using a phone, were included in the study. Exclusion Criteria:• Patients who could not be contacted during the study period, or those who developed post-operative complications (such as stenosis, necrosis, ileus, dermatitis, parastomal herniation, etc.) were excluded from the sample.","100 Years",{"count":399,"type":22},[52],"The planned research aims to evaluate the impact of a training program on self-efficacy in patients with permanent colostomies. It highlights the importance of holistic patient education in preventing complications and improving adaptation to stomas, which can positively affect patients' quality of life and self-efficacy.",[546,28],"Stoma Colostomy",[548,549,550,551],"stoma","Colo-rectal cancer","consulting","self-efficacy","2025-09-07",{"date":554,"type":33},"2025-09-12",{"date":556,"type":33},"2025-06-23",{"date":272,"type":22},{"name":559,"class":79},"Cukurova University",{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":18,"minAge":120,"maxAge":121,"enrollmentInfo":568,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":570,"conditions":571,"keywords":572,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":585,"locationsCount":138},"100604344","colorectal-analysis-for-signature-cancer-assessment-using-delta-hld-100604344","NCT07148297","Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD","Proof-of-concept Case-control Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CASCADE)","CASCADE","Inclusion Criteria:\n\n* Candidate for colonoscopy or colorectal surgery\n* Willing and able to provide informed consent\n* Able to provide blood and\u002For tissue sample before treatment or resection\n\nExclusion Criteria:\n\n* Prior history of colorectal cancer\n* Inflammatory bowel disease\n* Known hereditary cancer syndromes (e.g., Lynch, FAP)\n* Other active malignancies\n* Recent chemotherapy or immunosuppressive treatment",{"count":569,"type":22},600,"CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, for the detection of colorectal cancer. Epiliquid also integrates a proprietary bioinformatic system capable of identifying, ranking, and selecting tumor-specific methylation biomarkers for different cancer types. In this study, colorectal cancer-specific biomarkers will be evaluated in blood and tissue samples using delta-HLD technology, which enables sensitive and multiplexed detection through PCR. Study results will support the validation of Epiliquid's integrated platform as a minimally invasive and accessible diagnostic solution for colorectal cancer.",[28],[265,573,574,575,576,577,578],"Epigenetics","Liquid Biopsy","cfDNA","Biomarker","Methylation","PCR","2025-08-22",{"date":581,"type":33},"2025-08-29",{"date":583,"type":33},"2021-06-30",{"date":249,"type":22},{"name":586,"class":137},"Epiliquid Holding, Inc",{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":23,"phases":597,"briefSummary":598,"conditions":599,"keywords":608,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":138},"100601686","post-operative-hospital-at-home-after-colorectal-surgery-100601686","NCT07113717","Post Operative Hospital at Home After Colorectal Surgery","Early Post-operative Discharge of Colorectal Surgical Patients to a Virtual Hospital at Home Model (Post Operative Hospital at Home) - a Clinical Feasibility Study","POPHaH","Inclusion Criteria:\n\n* Planned minimally invasive (laparoscopic or robot-assisted) CRS\n* No epidural analgesia\n* No new stoma\n* Bleeding \\\u003C 500 ml\n* Actual condition assessed to be clinically stable\n* Meeting the Chung score discharge criteria for ambulatory surgery\n* Self-reliant or receives sufficient formal care to be care-independent of a primary informal caregiver\n* Home-based admission will be located within catchment area of the hospital (according to the official address of the individual)\n* Signed informed written and oral consent\n\nExclusion Criteria:\n\n* Patients who cannot comply with self-assessment\n* Improficiency in Danish\n* Pregnancy\n* Conversion to emergency surgery (uncontrolled perforation of bowel, ileus)\n* Complications during surgery warranting in-hospital admission (observation in intensive care unit or close observation from other specialities, e.g. cardiology)",{"count":596,"type":22},20,[52],"The goal of this feasibility study is to investigate whether a virtual Hospital at Home is safe and possible for patients undergoing planned minimally invasive colorectal surgery. The study aims to answer the following main questions:\n\nWhat are the patient- and next-of-kin-related effects, as well as the clinical and organizational effects, of home-based admission? What are the implementation barriers for a full-scale randomized controlled trial? Participants will follow a standardized protocol for their care befor, during and after surgery. However, the care after surgery will be conducted at home using telemedicine.",[28,600,601,602,603,604,605,606,607],"Colo-rectal Surgery","Colocolic and Ileocolic Anastomosis","Colon and\u002For Rectal Resection With Anastomosis for Cancer","Diverticular Disease of Colon","Colon Benign Tumor","Crohn Disease and Ulcerative Colitis","Ileostomy Closure","Stoma Reversal Procedure",[609,610],"hospital at home for colorectal surgery","postoperative hospital at home","2025-08-02",{"date":613,"type":33},"2025-08-11",{"date":615,"type":22},"2025-12-15",{"date":617,"type":22},"2027-06",{"name":619,"class":79},"Nordsjaellands Hospital",{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":4,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":18,"minAge":627,"maxAge":4,"enrollmentInfo":628,"targetDuration":4,"studyType":23,"phases":630,"briefSummary":631,"conditions":632,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":490},"100599490","phase-2-low-dose-trifluridinetipiracil-with-bevacizumab-in-mcrc-100599490","NCT07085169","Low-dose Trifluridine\u002FTipiracil With Bevacizumab in mCRC","Low-dose Trifluridine\u002FTipiracil With Bevacizumab in Refractory Metastatic Colorectal Cancer: a Multicenter, Single-arm, Phase 2 Study","Inclusion Criteria:\n\n1. age over 60 years old, male and female\n2. histologically confirmed adenocarcinoma of the colon or rectum\n3. patients with metastatic or advanced unresectable diseases who had received two or more previous chemotherapy regimens or intolerance to last regimen\n4. with or without measurable lesions\n5. ECOG 0 to 2, expected survival time over 3 months\n6. Enough organ functions that can tolerate treatment: Absolute neutrophil count (ANC) ≥1.5x109\u002FL, White blood count ≥3.5x109\u002FL, Platelets ≥75x109\u002FL, Hemoglobin (Hb) ≥80g\u002FL, ALT\u002FAST ≤2.5x ULN (for patient with liver metastasis ALT\u002FAST ≤5x ULN), Serum bilirubin ≤1.5x ULN, Serum creatinine ≤1.5x ULN.\n7. Signed informed consent and willing to follow the study protocol\n\nExclusion Criteria:\n\n1. symptomatic metastases of central nervous system\n2. other primary malignancies\n3. uncontrollable comorbidities, such as hypertension, thrombotic diseases, chronic kidney disease\n4. organ functions that cannot tolerate study treatment\n5. bowel obstruction or other conditions affecting oral administration\n6. allergic to study medication\n7. other conditions that patients are unsuitable for this study assessed by the investigators","60 Years",{"count":629,"type":22},50,[25],"This is a phase II, single-center, prospective trial aimed to investigate the efficacy and safety of a modified regimen of trifluridine\u002Ftipiracil plus bevacizumab in refractory metastatic colorectal cancer. Patients will be treated with trifluridine\u002Ftipiracil (17.5 mg\u002Fm2 dose orally twice daily, d1-10, every 14-days) plus bevacizumab (5mg\u002Fkg dose intravenously once at day 1, every 14-days). The study treatment will be administered until progression of disease, intolerable toxicity or withdraw of consent.",[28,633,634,635],"Third-line and Beyond Therapy","TAS 102","Bevacizumab","2025-07-24",{"date":638,"type":33},"2025-07-25",{"date":640,"type":22},"2025-08-01",{"date":642,"type":22},"2028-08-01",{"name":644,"class":79},"Ruijin Hospital",{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":650,"acronym":651,"eligibilityCriteria":652,"healthyVolunteers":119,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":653,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":655,"conditions":656,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":661,"leadSponsor":663,"locationsCount":4},"100599734","role-of-programmed-death-ligand-1-in-colorectal-cancer-100599734","NCT07088341","Role of Programmed Death Ligand 1 in Colorectal Cancer","the Role of Programmed Death Ligand 1 in Diagnosis of Colorectal Cancer","SPDL1","Inclusion Criteria:Patients at South Egypt Cancer institute and Assuit University Hospital Recently diagnosed as colorectal cancer patients at different stages.\n\n2\\. Patients did not undergo colorectal surgery\n\n\\-\n\nExclusion Criteria:\n\n\\-",{"count":654,"type":22},90,"1. \\- Evaluation of diagnostic importance of soluble programmed death ligand-1 in patient with recently diagnosed as Colorectal cancer at different stages of disease .\n2. Correlation of SPDL-1 level and clinco-pathological data of patients at presentation .",[28],"2025-07-19",{"date":659,"type":33},"2025-07-28",{"date":640,"type":22},{"date":662,"type":22},"2026-09-01",{"name":409,"class":79},{"id":665,"slug":666,"hasResults":12,"nctId":667,"briefTitle":668,"officialTitle":669,"acronym":4,"eligibilityCriteria":670,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":671,"enrollmentInfo":672,"targetDuration":4,"studyType":23,"phases":674,"briefSummary":675,"conditions":676,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":681,"completionDateStruct":683,"leadSponsor":685,"locationsCount":138},"100593175","phase-2-phase--clinical-trial-of-cadonilimab-combined-with-anti-angiogenic-agents-in-metastatic-dmmrmsi-h-crc-100593175","NCT07003022","Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR\u002FMSI-H CRC","An Open and Exploratory Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR\u002FMSI-H Colorectal Cancer","Inclusion Criteria:\n\n\\- Signed written informed consent prior to enrollment. Age 18-80 years. dMMR or MSI-H Diagnosis confirmed by histological examination and\u002For cytological examination combined with imaging assessment of advanced colorectal cancer.\n\nECOG score: 0 to 2. At least one measurable lesion (≥10 mm long diameter on CT scan for non-lymph node lesions and ≥15 mm short diameter on CT scan for lymph node lesions according to iRECIST criteria).\n\nAdequate organ function with. Routine blood: Absolute Neutrophil Count (ANC) 1.5 × 109\u002FL, Platelets (Platelet, PLT) ≥ 100 × 109\u002FL, Hemoglobin (HGB) ≥ 90 g\u002FL.\n\nLiver function: Total Bilirubin (TBIL) ≤ 1.5 × Upper Limit of Normal Value (ULN); Alanine Aminotransferase (ALT) and Aspartate Transferase (AST) ≤3×ULN; serum albumin ≥30 g\u002FL; after conventional hepatoprotective treatment meeting the above criteria, and can be stable for at least 1 week after evaluation by the investigator can be enrolled.\n\nRenal function: Creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL\u002Fmi (applying the standard Cockcroft-Gault formula).\n\nCoagulation function: International Normalized Ratio (INR) ≤ 1.5 \u002FPT ≤ 1.5 × ULN, aPTT ≤ 1.5 × ULN; if the subject is receiving anticoagulation therapy, as long as PT and INR are within the range drawn up by anticoagulant drugs.\n\nA predicted survival of ≥ 3 months. Female patients must be non-pregnant and non-lactating and are required to use a medically approved form of contraception (e.g., IUD, pill or condom) during study treatment and for at least 120 days after study completion, and are not allowed to donate eggs to another person or freeze them for fertilization and propagation during this period.\n\nExclusion Criteria:\n\n* Symptomatic brain metastases. A prior history of a primary tumor outside of the colorectal cancer in 3 years Active autoimmune disease or autoimmune disease with potential for recurrence such as, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enterocolitis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism, previous thyroid surgery cannot be included; subjects with vitiligo or complete remission of asthma in childhood and adult who do not require any intervention afterwards can be included; subjects with asthma requiring medical intervention with bronchodilators cannot be included.\n\nSubjects with any severe and\u002For uncontrolled disease. including. Poorly controlled blood pressure (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg); poorly controlled diabetes (fasting blood glucose \\[FBG\\] \\> 10 mmol\u002FL) Having ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia (QTc ≥ 470ms) and ≥ grade 2 congestive heart failure (New York Heart Association \\[NYHA\\] classification) Active or uncontrolled severe infection (≥ CTCAE grade 2 infection) requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection Active hepatitis (transaminases do not meet the inclusion criteria, hepatitis B reference: HBV DNA ≥ 1000 IU\u002Fml or ≥ 10\\^4 copies\u002Fml; hepatitis C reference: HCV RNA ≥ 1000 IU\u002Fml or ≥ 10\\^4 copies\u002Fml; after nucleotide based antiviral therapy below the above criteria, can be enrolled); chronic hepatitis B virus carriers with HBV DNA \\\u003C 10\\^4 IU\u002Fml, who must receive concomitant antiviral therapy during the trial to be enrolled.\n\nThose with renal failure requiring hemodialysis or peritoneal dialysis. Those with a history of immunodeficiency, including HIV-positive or suffering from other acquired or congenital immunodeficiency diseases, or a history of organ transplantation Active autoimmune disease requiring systemic therapy (e.g., use of disease-relieving drugs, corticosteroids, or immunosuppressive agents) within 2 years prior to the start of study treatment, except for replacement therapies (e.g., thyroxine, insulin, or physiologic corticosteroids for adrenal or pituitary insufficiency); receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy. Doses \\>10 mg\u002Fday of prednisone or other equivalent hormone and within 2 weeks of the first dose and still continuing Those with a history of active tuberculosis Those who fail to control and still require repeated drainage of ascites, pericardial effusion, pleural effusion.\n\nResearch treatment related to. Patients who have undergone major organ transplantation Those who have undergone major surgical treatment, incisional biopsy or significant traumatic injury within 28 days prior to the start of study treatment; or have a long-standing untreated wound or fracture History of live attenuated vaccination within 14 days prior to the start of study treatment or planned live attenuated vaccination during the study History of severe hypersensitivity reactions following the use of monoclonal antibodies; known hypersensitivity to active ingredients or excipients such as envafolimab, lenvatinib, etc., of this study drug Those who are participating or have participated in other clinical studies within 4 weeks prior to the start of the study Those who have received PD-1\u002FCTLA-4 dual immunotherapy during previous treatment.\n\nThose with a history of severe allergy. Women who are pregnant or breastfeeding At risk for bleeding, or with coagulation disorders, or undergoing thrombolytic therapy Those with a history of psychotropic substance abuse and unable to abstain or with psychiatric disorders Subjects who, in the judgment of the investigator, have a concomitant disease that seriously jeopardizes the safety of the subject or interferes with the completion of the study, or subjects for whom other reasons are deemed to exist that make them unsuitable for enrollment In the judgment of the investigator, subjects who, in the judgment of the investigator, have a concomitant disease that seriously jeopardizes the safety of the subject or interferes with the completion of the study, or subjects for whom other reasons are deemed to exist that make them unsuitable for enrollment.","80 Years",{"count":673,"type":22},40,[25],"This study is a prospective, open-label, dual-arm exploratory Phase II clinical trial designed to assess the efficacy and safety of cadonilimab combined with anti-angiogenic agents in patients with dMMR\u002FMSI-H recurrent or metastatic colorectal cancer. Eligible patients are enrolled into two cohorts based on their prior exposure to PD-1\u002FPD-L1 antibody therapy: Cohort A (immune-naive group - patients with no prior PD-1\u002FPD-L1 treatment) and Cohort B (immune rechallenge group - patients who previously received and failed PD-1\u002FPD-L1 therapy). All participants receive combination therapy with cadonilimab and an anti-angiogenic agent, which is selected by the investigator from bevacizumab, regorafenib, or fruquintinib. Treatment continues until the occurrence of intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up, death, other conditions deemed by the investigator to warrant discontinuation, or study termination-whichever occurs first. Cadonilimab treatment will not exceed two years. Tumor response is evaluated every six weeks using RECIST v1.1 criteria. Safety is assessed using CTCAE v5.0, and adverse events are recorded from the first dose to 30 days after the end of treatment.",[28,677],"MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers","2025-06-02",{"date":680,"type":33},"2025-06-04",{"date":682,"type":22},"2025-06-01",{"date":684,"type":22},"2028-05-01",{"name":686,"class":79},"Fudan University"]